24. Aug 2026
Description
(AWP Alliance News) - Roche won FDA clearance for its Elecsys pTau217 blood test, positioning the group to push Alzheimer's assessment deeper into routine care and broaden the addressable testing market. The clearance gives Roche a first-mover edge in a single blood test positioned to support both rule-in and rule-out decisions, tightening its competitive stance against imaging and spinal-fluid pathways that can limit patient throughput.
The rollout is designed to scale quickly across more than 4,500 installed cobas instruments in the US, leveraging existing lab capacity rather than new capital spending. Roche developed the test with Eli Lilly, strengthening its role in the Alzheimer's care pathway as demand rises for earlier, more accessible evaluation.
https://www.prnewswire.com/news-releases/roche-receives-fda-clearance-f…
Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief via PR Newswire on August 24, 2026, and is solely responsible for the information contained therein.
